(Q35020833)

5 August 2017

1 reference

title

Management of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B. (English)

1 reference

5 August 2017

1 reference

1 reference

1

0 references

publication date

1 December 2002

1 reference

Journal of Gastroenterology and Hepatology

5 August 2017

published in

1 reference

5 August 2017

volume

17 Suppl 3

1 reference

5 August 2017

page(s)

S333-7

1 reference

Lamivudine therapy of WHV-infected woodchucks.

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S3.23.X

Drug therapy for chronic hepatitis B: antiviral efficacy and influence of hepatitis B virus polymerase mutations on the outcome of therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S3.23.X

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S3.23.X

Anti-HIV and anti-HBV activity and resistance profile of 2',3'-dideoxy-3'-thiacytidine (3TC) and its arylphosphoramidate derivative CF 1109.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S3.23.X

Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC (3TC) resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S3.23.X

Mutations in the hepatitis B virus polymerase gene associated with antiviral treatment for hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S3.23.X

Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S3.23.X

Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S3.23.X

Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S3.23.X

Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S3.23.X

Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S3.23.X

Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S3.23.X

Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S3.23.X

Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S3.23.X

The sequential occurrence of viral mutations in a liver transplant recipient re-infected with hepatitis B: hepatitis B immune globulin escape, famciclovir non-response, followed by lamivudine resistance resulting in graft loss.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S3.23.X

The impact of drug resistance on the effectiveness of chemotherapy for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S3.23.X

Prevalence of hepatitis C virus infection in patients with antiphospholipid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S3.23.X

Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S3.23.X

Protein kinase C-dependent distribution of the multidrug resistance protein 2 from the canalicular to the basolateral membrane in human HepG2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S3.23.X

A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S3.23.X

A preliminary trial of lamivudine for chronic hepatitis B infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S3.23.X

Lamivudine as initial treatment for chronic hepatitis B in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S3.23.X

Lamivudine resistance inimmunocompetent chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S3.23.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S3.23.X

Prednisolone priming enhances Th1 response and efficacy of subsequent lamivudine therapy in patients with chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S3.23.X

10.1046/J.1440-1746.17.S3.23.X

21 January 2018

Identifiers

DOI

1 reference

release_a25nzganube5zl5lskiy7hupea

5 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/a25nzganube5zl5lskiy7hupea

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference